Biotin-Acridine Red Cell Exchange Kinetics
← catalyst calendarNCT07155031 · readout in 42 d
Sponsored by Cerus Corporation (industry) · CERS — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Na · None · Supportive care
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
This study has been suspended due to a lack of funding. The protocol will be reconsidered within the next 6-12 months if/as funding becomes available.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-15 | estimated | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sickle Cell Disease
Intervention
- Device: Pathogen reduced red blood cells — also filed as Biotin
Primary outcomes
what the primary-completion date above is the date OFRecovery
measured 24 hour
Correlation between the biotin and acridine markers
measured 6 months
Survival
measured 6 months
Acridine loss
measured 6 months
Permalink · CERS's whole pipeline · Catalyst calendar · Every registered study · What changed